Sicor Overview
- Year Founded
-
1986
- Status
-
Acquired/Merged
- Employees
-
174
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.4B
Sicor General Information
Description
Manufacturer of generic injectable pharmaceuticals designed for medical treatments. The company utilizes internal research and development capabilities, along with manufacturing and regulatory expertise to produce generic finished-dosage injectable pharmaceuticals and active pharmaceutical ingredients, providing pharmaceutical companies with generic biopharmaceuticals, inhalation ingredients, topical ingredients, and nasal ingredients.
Contact Information
Corporate Office
- 19 Hughes
- Irvine, CA 92618
- United States
Corporate Office
- 19 Hughes
- Irvine, CA 92618
- United States
Sicor Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 22-Jan-2004 | $3.4B | Completed | Generating Revenue | ||
| 4. PIPE | 20-May-1997 | Completed | Generating Revenue | |||
| 3. IPO | 05-Jun-1990 | Completed | Generating Revenue | |||
| 2. Corporate | 08-Feb-1990 | $15M | $25.6M | Completed | Generating Revenue | |
| 1. Early Stage VC | 05-Sep-1989 | $10.6M | $10.6M | Completed | Generating Revenue |
Sicor Patents
Sicor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2012061469-A2 | Crystalline forms of pralatrexate | Inactive | 02-Nov-2010 | ||
| WO-2012061469-A3 | Crystalline forms of pralatrexate | Inactive | 02-Nov-2010 | ||
| WO-2011100325-A2 | Polymorphs of sunitinib salts | Inactive | 09-Feb-2010 | ||
| WO-2011100325-A3 | Polymorphs of sunitinib salts | Inactive | 09-Feb-2010 | ||
| EP-2520581-A1 | Method for the determination the purity of 5-azacytidine | Inactive | 06-Aug-2008 | C07H1/00 |
Sicor Signals
Sicor Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Chancellor Capital Management | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Fairfield Ventures | Venture Capital | Minority |
Sicor Investments & Acquisitions (2)
Sicor’s most recent deal was a Secondary Transaction - Private with Diaspa for . The deal was made on 01-Jul-1998.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Diaspa | 01-Jul-1998 | Secondary Transaction - Private | Other Commercial Services | ||
| Diaspa | 29-Dec-1997 | Merger/Acquisition | Other Commercial Services |
Sicor FAQs
-
When was Sicor founded?
Sicor was founded in 1986.
-
Where is Sicor headquartered?
Sicor is headquartered in Irvine, CA.
-
What is the size of Sicor?
Sicor has 174 total employees.
-
What industry is Sicor in?
Sicor’s primary industry is Pharmaceuticals.
-
Is Sicor a private or public company?
Sicor is a Private company.
-
What is the current valuation of Sicor?
The current valuation of Sicor is .
-
What is Sicor’s current revenue?
The current revenue for Sicor is .
-
How much funding has Sicor raised over time?
Sicor has raised $76.4M.
-
Who are Sicor’s investors?
3i Group, Abingworth, Chancellor Capital Management, Domain Associates, and Fairfield Ventures are 5 of 12 investors who have invested in Sicor.
-
When was Sicor acquired?
Sicor was acquired on 22-Jan-2004.
-
Who acquired Sicor?
Sicor was acquired by Teva Pharmaceutical Industries.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process